RBC Capital Maintains Outperform on Sangamo Therapeutics, Lowers Price Target to $6
Portfolio Pulse from richadhand@benzinga.com
RBC Capital analyst Luca Issi has maintained an 'Outperform' rating on Sangamo Therapeutics (NASDAQ:SGMO), but lowered the price target from $8 to $6.

August 09, 2023 | 3:05 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Sangamo Therapeutics' price target has been lowered from $8 to $6 by RBC Capital, though the 'Outperform' rating is maintained.
The lowering of the price target by RBC Capital indicates a potential decrease in the stock's value in the short term. However, the maintained 'Outperform' rating suggests that the stock is still expected to outperform the market or its sector, which could mitigate some of the negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100